Tetra Bio Pharma to begin in-life trial for its CBD-based cancer pain drug QIXLEEF

Tetra Bio-Pharma Inc (TSE:TBP) (OTCQB:TBPMF) VP of Clinical Operations Aurelia De Pauw tells Proactive the group is beginning the in-life phase of its CBD-based cancer pain drug QIXLEEF after the drug was shipped by its producer Aphria Inc.

De Pauw says the trial, known as Plenitude, will test the efficacy and safety of inhaled QIXLEEF for the relief of pain in 78 cancer patients, which it is currently enrolling.

source